IPA (ImmunoPrecise Antibodies)

Highlights from JPM Healthcare 2024 🧬 It's the "Year of the Antibody" at JPM Healthcare 2024, and we're buzzing with excitement! Dr. Jennifer Bath, CEO of IPA, participated as a panelist in the sold-out discussion titled "Connecting Clusters of Excellence: Europe as Your Gateway to Global Success". Key takeaways: • Leveraging local innovation hubs effectively to create expansive global networks. • Building teams strategically with diverse experts to fuel innovation. • Belgium's favorable tax and IP policies position it as a strategic hub for life sciences. Insightful hands-on contributions from our esteemed fellow panelists Ann Belien, PhD, Youri De Groote, Robert Darwin and John Baekelmans enriched the discussion. Thank you, Health Campus Limburg DC, Yu Chen, Sara Smeets and Roeland Buckinx for organizing this impactful event. Stay connected for more updates from JPM and the forefront of healthcare innovation! Let's start the conversation on leveraging global hubs. https://bit.ly/46XqDLE #JPMHealthcare #JPM24 #Innovation #LifeSciences #GlobalNetworks #AI #ArtificialIntelligence #Antibodies #Biotechnology #healthcampuslimburgDC BioCentury Inc. Sidley Austin LLP flanders.bio Korea Biotechnology Industry Organization (KoreaBIO) Jennifer Bath, Ph.D.

Follow us to get first access to latest news, insightful advancements, industry trends, and strategies to thrive in today's competitive antibody discovery sector. From AI in drug discovery to accelerating your program, we are here to share actionable knowledge that propels your research forward. Topics include: • In silico advancements • Optimizing bispecifics • Diversity-driven use cases • VHH versatility and high affinity #Antibodies #mAb #DrugDiscovery #ArtificialIntelligence #Ai #TechBio

Our commitment to innovation in the biologics industry has led us to achieve a remarkable 100% success rate yielding high affinity pairs in anti-drug and anti-idiotypic antibody development with rapid turnaround time. By leveraging advanced technologies and unparalleled expertise, we are setting new industry standards in customization, precision and reliability, driving forward the future of therapeutic solutions. Join us as we continue to push the boundaries of what's possible in drug discovery. Let's start the conversation on how an end-to-end customized solution can accelerate and reduce costs for you: https://bit.ly/3zSL4yd #mAb #AntiIdiotypic #Biotech #Antibodies #lifescience

Join us at ADLM in Chicago, July 28th-August 1st! Explore the forefront of diagnostic antibodies, protein production, and tool innovation. As a #1 ranked CRO with extensive experience and a high success rate, we're excited to share our latest technologies, statistics and results. Let's start the conversation how our global labs in both Europe and North America can best support your needs. Join us at booth 1564 - see you there! #ADLM #Biotherapeutics #Antibodies #mAb #Innovation #DiagnosticAntibodies #AntibodyReagents

We're celebrating another win! BioStrand (a subsidiary of IPA), also won the Best Demo award for the most creative use of AI technology at the InterSystems Global Summit in June! We proudly took home the prestigious Impact Award as well. Thank you to InterSystems for an invitation to the event. LENSᵃⁱ™ Integrated Intelligence Technology Vector Search capabilities, with InterSystems inside, recently launched. LENSᵃⁱ’s foundational AI model powered by HYFT® technology is revolutionizing drug discovery by leveraging vector search to map complex relationships between data points. This innovative approach identifies similarities and patterns across vast biological datasets, uncovering potential drug candidates faster and more efficiently. By uniting text, sequence, structure, and function into a single platform, LENSᵃⁱ streamlines the drug discovery and development process, making data useful in unprecedented ways. Want to see what it can do for you? Contact us for a live demo: https://bit.ly/46e9SNb InterSystems #VectorSearch #DrugDiscovery #mAb #Antibodies #TechBio #Biotech

Mark your calendars for the upcoming Q4 and fiscal year end 2024 earnings conference call. Join us July 25, 2024, at 10:30am EST for an update on quarterly results with key insights on strategic and forward progress. Participant Dial-In Details: Participants call one of the allocated dial-in numbers (below) and advise the Operator of either the Conference ID 9236374 or Conference Name. North America Toll-Free: (888) 550-5658 North America Toll: (646) 960-0289 International Toll: 1(646) 960-0289 Webcast Details: Attendee URL:https://bit.ly/4f1vnoG See full release: https://bit.ly/3S4iLDi

In case you missed our co-hosted symposium with Carterra, the presentations are now available! Discover how IPA and BioStrand are pushing the boundaries of antibody discovery and development strategies with a cutting-edge combination of in silico, in vitro, and in vivo insights. Our approach is driven by diversity, de-risking, and data-driven decision making. A big thank you to everyone who attended the symposium at the state-of-the-art IPA Utrecht facility! See the presentations: https://bit.ly/4bBzkgV Let's explore how the technology can make a difference for you: https://bit.ly/4cyfdkO #DrugDiscovery #Biotech #Antibodies #TechBio #AI #ArtificialIntelligence Ilse Roodink, Ph.D. Julie Delanote Carterra BioStrand (a subsidiary of IPA)

Great to see several of you at the Antibody Therapeutics hubXchange in Boston! Shuji Sato, IPA Senior Director of Client Relations, highlighted the trending topic of VHH Discovery in "Maximizing VHH Lead Generation for Therapeutic Breakthroughs." He discussed IPA's deep experience in this area and why VHHs are gaining attention, including their versatility and advantages in bi-specific antibody and CAR development. We look forward to continuing these conversations and innovations in VHH discovery and development! If you missed it, check out the poster and let's connect to explore how a customized solution could make a difference for you: https://bit.ly/3zocSKC #HUBxchange #VHHDiscovery #Therapeutics #Biotech #BiSpecifics

At the heart of our organization lies the belief in celebrating the talents and contributions of every team member. Each individual's dedication and passion drive our success, creating a vibrant and dynamic workplace. Together, we build a culture where everyone can thrive and achieve their best, embracing diversity and inclusion. Happy pride month! #Pride2024 #DEI

ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer. Ms. Taylor is a seasoned financial executive with extensive experience in both early-stage and large growth companies, including those privately held, private equity-backed, and publicly listed. She has a strong background in driving growth, establishing infrastructure, and implementing effective strategies for value creation in dynamic, scaling environments. See full release: https://bit.ly/4cIij5H